Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 dose-ranging study of ABT-126 in mild to moderate Alzheimer's disease
2011-002004-32Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Oct 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of nelonicline in Alzheimer's disease (AD), sponsored by AbbVie Inc.. Started Oct 2011; status: completed.
02
Drugs
nelonicline
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2011-002004-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002004-32.